{
  "pmcid": "8223138",
  "sha256": "18b8850b54a3d82f531c1079a493aa250f018f824f8838ba4552ad4f90690ed7",
  "timestamp_utc": "2025-11-09T22:57:45.575636+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.299679487179485,
    "reading_ease": 38.58490384615385,
    "word_count": 234
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This multicenter, open-label, phase 3 randomised controlled trial enrolled 451 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "451 patients with stage T1-4N1M0/T4N0M0 thoracic ESCC from eight centers in China"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to receive NCRT plus surgery or surgery alone"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery versus surgery alone for long-term survival."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was overall survival (OS)"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 224 patients were randomised to the NCRT group and 227 to the surgery group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The intention-to-treat analysis included all participants."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The NCRT group showed improved OS (hazard ratio [HR], 0.74; 95% CI, 0.57-0.97; P = 0.03) and DFS (HR, 0.60; 95% CI, 0.45-0.80; P < 0.001) compared to the surgery group."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the NCRT group, with 54.3% experiencing grade 3 or 4 hematologic toxic effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ClinicalTrials.gov Identifier: NCT01216527."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}